Complementary and alternative medicinal effects of broccoli sprouts powder on Helicobacter pylori eradication rate in type 2 diabetic patients: A randomized clinical trial

Journal of Functional Foods

Volumn 7, Issue 1, 2014, Pages 390-397

  Bahadoran, Zahra ^a,b   Mirmiran, Parvin ^c,d   Yeganeh, Maryam Zarif ^a,b   Hosseinpanah, Farhad ^b   Zojaji, Homayoun ^c   Azizi, Fereidoun ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Shahid Beheshti University of Medical Sciences   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Research Center for Gastroenterology and Liver Disease Department of Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences ^*  (Iran)

Author keywords

Broccoli sprouts powder; Gastric inflammation; Helicobacter pylori; Insulin resistance; Standard triple therapy

Indexed keywords

EID: 84897975997     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2014.01.020     Document Type: Article

References (40)

1. Arinton I.G. Serum gastrin level and pepsinogen I/II ratio as biomarker of Helicobacter pylori chronic gastritis. Acta Medica Indonesiana 2010, 42:142-146.
2. Aydemir S., Bayraktaroglu T., Sert M., Sokmen C., Atmaca H., Mungan G., Gun B.D., Borazan A., Ustundag Y. The effect of Helicobacter pylori on insulin resistance. Digestive Diseases and Sciences 2005, 50:2090-2093.
3. Bahadoran Z., Mirmiran P., Azizi F. Potential efficacy of broccoli sprouts as a unique supplement for management of type 2 diabetes and its complications. Journal of Medicinal Food 2013, 16:375-382.
4. Bahadoran Z., Mirmiran P., Hosseinpanah F., Hedayati M., Hosseinpour-Niazi S., Azizi F. Broccoli sprouts reduce oxidative stress in type 2 diabetes: A randomized double-blind clinical trial. European Journal of Clinical Nutrition 2011, 65:972-977.
5. Bahadoran Z., Mirmiran P., Hosseinpanah F., Rajab A., Asghari G., Azizi F. Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Diabetes Research and Clinical Practice 2012, 96:348-354.
6. Biemond I., Kreuning J., Jansen J.B., Lamers C.B. Serum pepsinogens in patients with gastric diseases or after gastric surgery. Scandinavian Journal of Gastroenterology 1994, 29:238-242.
7. Bodger K., Wyatt J.I., Heatley R.V. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter 2001, 6:216-224.
8. Bölükbaş C., Bölükbaş F.F., Ovünç O., Kiliç G., Dalay R., Güven H., Uras F., Yardimci T.K., Sökmen M.H., Agan A.F., Pişkinpaşa N. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis. The Turkish Journal of Gastroenterology 2006, 17:172-176.
9. Chen T.S., Tsay S.H., Chang F.Y., Lee S.D. Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: A 12-month follow-up study. American Journal of Gastroenterology 1994, 89:1511-1514.
10. Fahey J.W., Haristoy X., Dolan P.M., Kensler T.W., Scholtus I., Stephenson K.K., Talalay P., Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:7610-7615.
11. Fahey J.W., Stephenson K.K., Wade K.L., Talalay P. Urease from Helicobacter pylori is inactivated by sulforaphane and other isothiocyanates. Biochemical and Biophysical Research Communications 2013, 435:1-7.
12. Galan M.V., Kishan A.A., Silverman A.L. Oral broccoli sprouts for the treatment of Helicobacter pylori infection: A preliminary report. Digestive Diseases and Sciences 2004, 49:1088-1090.
13. Gasparetto M., Pescarin M., Guariso G. Helicobacter pylori eradication therapy: Current availabilities. ISRN Gastroenterology 2012, 2012:186734.
14. Go M.F. Review article: Natural history and epidemiology of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 2002, 16:3-15.
15. Gunji T., Matsuhashi N., Sato H., Fujibayashi K., Okumura M., Sasabe N., Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. American Journal of Gastroenterology 2008, 103:3005-3010.
16. Gunji T., Matsuhashi N., Sato H., Fujibayashi K., Okumura M., Sasabe N., Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009, 14:144-150.
17. Haristoy X., Angioi-Duprez K., Duprez A., Lozniewski A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrobial Agents and Chemotherapy 2003, 47:3982-3984.
18. Keenan J.I., Salm N., Hampton M.B., Wallace A.J. Individual and combined effects of foods on Helicobacter pylori growth. Phytotherapy Research 2010, 24:1229-1233.
19. Keenan J.I., Salm N., Wallace A.J., Hampton M.B. Using food to reduce H. pylori-associated inflammation. Phytotherapy Research 2012, 26:1620-1625.
20. Lee S.Y., Shin Y.W., Hahm K.B. Phytoceuticals: Mighty but ignored weapons against Helicobacter pylori infection. Journal of Digestive Diseases 2008, 9:129-139.
21. Luis D.A., Lahera M., Cantón R., Boixeda D., San Román A.L., Aller R., Aller R., de La Calle H. Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. Diabetes Care 2008, 21:1129-1132.
22. Mario F., Cavallaro L.G. Non-invasive tests in gastric diseases. Digestive and Liver Disease 2008, 40:523-530.
23. Martínez Torres A., Martínez Gaensly M. Helicobacter pylori: A new cardiovascular risk factor?. Revista Espanola de Cardiologia 2002, 55:652-656.
24. Mirmiran P., Bahadoran Z., Hosseinpanah F., Keyzad A., Azizi F. Effects of broccoli sprout with high sulforaphane concentration on inflammatory markers in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Journal of Functional Foods 2012, 4:837-841.
25. Mohamadkhani A., Darvish Moghaddam S., Salmanroghani H., Allafsghari A., Yazdanbod A., Mirzaei M., Haj-sheykholeslami A., Bashiri J., Sadjadi A., Massarrat S. Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence?. Archives of Iranian Medicine 2013, 16:208-212.
26. Moreno D.A., Carvajal M., López-Berenguer C., García-Viguera C. Chemical and biological characterisation of nutraceutical compounds of broccoli. Journal of Pharmaceutical and Biomedical Analysis 2006, 41:1508-1522.
27. Naito Y., Yoshikawa T. Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. Free Radical Biology and Medicine 2002, 33:323-336.
28. Naja F., Nasreddine L., Hwalla N., Moghames P., Shoaib H., Fatfat M., Sibai A., Gali-Muhtasib H. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter 2012, 17:444-451.
29. Noto J.M., Peek R.M. Helicobacter pylori: An overview. Methods in Molecular Biology 2012, 921:7-10.
30. Ohkusa T., Miwa H., Nomura T., Asaoka D., Kurosawa A., Sakamoto N., Abe S., Hojo M., Terai T., Ogihara T., Sato N. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: Comparison with H. pylori-negative patients. Alimentary Pharmacology & Therapeutics 2004, 20:25-32.
31. Ojetti V., Pellicano R., Fagoonee S., Migneco A., Berrutti M., Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Medica 2011, 101:115-119.
32. Paik C.N., Chung I.S., Nam K.W., Kwon J.H., Chang J.H., Suh J.P., Park J.M., Cho Y.K., Lee I.S., Kim S.W., Choi M.G. Relationship between pepsinogen I/II ratio and age or upper gastrointestinal diseases in Helicobacter pylori-positive and -negative subjects. Korean Journal of Gastroenterology 2007, 50:84-91.
33. Park S.M., Park J., Chang S.K., Yoo B.C., Kim H.J. Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: Effect of bacterial eradication. Korean Journal of Internal Medicine 1996, 11:1-8.
34. Polyzos S.A., Kountouras J., Zavos C., Deretzi G. Helicobacter pylori and insulin resistance association: not just a myth, not yet a fact. Saudi Journal of Gastroenterology 2011, 17:425-426.
35. Polyzos S.A., Kountouras J., Zavos C., Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011, 16:79-88.
36. Polyzos S.A., Kountouras J., Zavos C., Deretzi G. The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance. Clinics (Sao Paulo) 2011, 66:911-912.
37. Rossi C., Quadri R., Cavallo Perin P. Helicobacter pylori infection and diabetic complications. Diabetes, Nutrition and Metabolism 2004, 17:65-68.
38. Sato K., Kawakami N., Ohtsu T., Tsutsumi A., Miyazaki S., Masumoto T., Horie S., Haratani T., Kobayashi F., Araki S. Broccoli consumption and chronic atrophic gastritis among Japanese males: An epidemiological investigation. Acta Medica Okayama 2004, 58:127-133.
39. Yanaka A., Fahey J.W., Fukumoto A., Nakayama M., Inoue S., Zhang S., Tauchi M., Suzuki H., Hyodo I., Yamamoto M. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prevention Research (Phila) 2009, 2:353-360.
40. Zhou X., Zhang C., Wu J., Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: A meta-analysis of observational studies. Diabetes Research and Clinical Practice 2013, 99:200-208.